Register Login

RAPT Therapeutics Inc (RAPT)

  • Event
  • May 23, 2022, 12:16 UTC

(10% Negative) RAPT Therapeutics, Inc. (RAPT) Announces Delay in trial Trials for atopic dermatitis Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 1, 2025, 9:47 p.m.

    📋 RAPT Therapeutics, Inc. (RAPT) - Clinical Trial Update

    Filing Date: 2022-05-23

    Accepted: 2022-05-23 08:16:32

    Event Type: Clinical Trial Update

    Event Details:

    RAPT Therapeutics Inc (RAPT) Announces Clinical Trial Update RAPT Therapeutics Inc (RAPT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: trial, needs
    • Diseases/Conditions: atopic dermatitis
    • Clinical Stage: clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: RAPT Therapeutics, Inc.
      • targeting this pathway. Patients with AD express higher levels of CCR4 ligands compared with healthy humans; these ligands also correlate with the severity of disease. RAPT believes that by inhibiting CCR4, RPT193 has the potential to bring therapeutic benefit to patients across a broad spectrum of inflammatory diseases, including AD, asthma, chronic spontaneous urticaria, allergic rhinitis with nasal polyps, chronic rhinosinusitis and eosinophilic esophagitis. About Atopic Dermatitis Atopic dermatitis is a highly prevalent chronic, inflammatory skin disease characterized by skin barrier disruption and immune dysregulation. Patients with AD have chronically inflamed skin lesions that can cause debilitating pruritus (itch), which can severely impair quality of life. While there is a marketed injectable product for the treatment of AD, RAPT believes RPT193, if approved, could fill an unmet medical need for the treatment of inflammatory disorders with the convenience of once-daily oral dosing. There are approximately 19 million adults and approximately 10 million children affected by AD in the United States. About RAPT Therapeutics, Inc. RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The company is also pursuing a range of targets that are in the discovery stage of development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: RAPT Therapeutics Inc
    • CIK: 0001673772
    • Ticker Symbol: RAPT
    • Period End Date: 2022-05-23
    • Document Type: 8-K

Search

News categories